Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

Learn more about whether ACADIA Pharmaceuticals Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Moderna, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Lonza Group AG / Key word (s): Annual Results/Sustainability Lonza Publishes Invitation to the 2025 Annual General Meeting and 2024 Annual and Sustainability Reports 03-Apr-2025 / 07:00 CET/CEST ...

Moderna shares may remain under the microscope on Tuesday after sinking to a five-year low following news that the Food and ...

Shares in Moderna and Novavax fell Monday, following a Wall Street Journal report that the Food and Drug Administration’s top vaccine official has been pushed out. Shares in some larger drugmakers, ...

CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK has granted marketing authorization for mRESVIA (mRNA-1345), indicated for ...

CureVac N.V. secured funding with GSK amid financial struggles, while a key patent win boosts stock. Click for why my ...

GEO-CM04S1 BARDA/Project NextGen Phase 2b trial preparations ongoing with manufacturing of clinical trial materials underway ...

The Trump administration’s decision to cut funding for Gavi, as part of a broader reduction in foreign aid, may have ...

It's been nearly five years since Moderna (NASDAQ ... Shifting sentiment about the need for annual booster vaccination, competition from alternative therapeutics, and the withdrawal of emergency ...